- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Anaheim, California • Fountain Valley, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2137–2160
of 13,800
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Dose Fractionation
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Dallas, Texas
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Interventions
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 58
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 31 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Placebo, Cladribine Low Dose, Cladribine High Dose
- Other · Drug
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Longmont, Colorado • Farmington, Connecticut + 20 more
- Conditions
- Zenker Diverticulum
- Interventions
- ZPOEM
- Procedure
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Thromboembolism
- Interventions
- Pharmacogenetic, Target INR 1.8
- Genetic · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 1,598 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
- Interventions
- HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)
- Drug
- Lead sponsor
- Hemab ApS
- Industry
- Eligibility
- 16 Years to 69 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
- Conditions
- Nephritis, Systemic Lupus Erythematosus
- Interventions
- AMG 811
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Danbury, Connecticut • Kansas City, Kansas + 5 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 25
- States / cities
- Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more
- Conditions
- Recurrent Glioblastoma or Other Glioma Subtypes
- Interventions
- BGJ398
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 14
- States / cities
- Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 20
- States / cities
- Berkeley, California • Duarte, California • Stanford, California + 15 more
- Conditions
- Laxity; Skin
- Interventions
- MCD
- Device
- Lead sponsor
- Cytrellis Biosystems, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Sacramento, California • Miami, Florida • New York, New York + 2 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Pridopidine
- Drug
- Lead sponsor
- Prilenia
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
- Conditions
- Glabellar Lines
- Interventions
- AGN-151586
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Los Angeles, California + 36 more
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Interventions
- Vigil™ Vaccine, Carboplatinum, Carboplatinum and Taxol
- Biological · Drug
- Lead sponsor
- Gradalis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland, Thyroid Hormones
- Interventions
- Armour® Thyroid, Levothyroxine
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Greenbrae, California + 23 more
- Conditions
- Healthy
- Interventions
- LY3478006 - IV, LY3478006 - SC, Placebo - IV, Placebo - SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
- Conditions
- Colorectal Cancer
- Interventions
- Blood Sample Collection
- Other
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 23,494 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 194
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 160 more
- Conditions
- Type 1 Diabetes
- Interventions
- Teplizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Not listed
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Decitabine 20 mg/m^2, Talacotuzumab 9 mg/kg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • New Orleans, Louisiana + 8 more
- Conditions
- Suicidal Ideation, Suicide Attempt, Anxiety, Depression Disorders
- Interventions
- Peer Support Services Recovery
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 15 Years to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non-Ischemic Central Retinal Vein Occlusion
- Interventions
- Active bevacizumab and Sham dexamethasone, Active bevacizumab and Active dexamethasone
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas